SCOPUS 정보 검색 플랫폼

Gastroenterology and Hepatology

Volumn 4, Issue 7, 2008, Pages 467-468

Certolizumab pegol for moderate-to-severe Crohn's disease

(1) Sandborn, William J a

a MAYO CLINIC COLLEGE OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB;

CROHN DISEASE; CROHNS DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; INJECTION SITE REACTION; LUPUS ERYTHEMATOSUS; MAINTENANCE THERAPY; REMISSION; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 49149084529 PISSN: 15547914 EISSN: None Source Type: Journal
DOI: None Document Type: Review

Times cited : (4)

References (3)

1
- 34447515607
- Maintenance therapy with certolizumab pegol for Crohn's disease
- Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
- (2007) N Engl J Med , vol.357 , pp. 239-250
- Schreiber, S.¹ Khaliq-Kareemi, M.² Lawrance, I.C.³ Thomsen, O.O.⁴ Hanauer, S.B.⁵

2
- 34447523749
- Certolizumab pegol for the treatment of Crohns disease
- Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, et al. Certolizumab pegol for the treatment of Crohns disease. N Engl J Med. 2007;357:228-238.
- (2007) N Engl J Med , vol.357 , pp. 228-238
- Sandborn, W.J.¹ Feagan, B.G.² Stoinov, S.³ Honiball, P.J.⁴ Rutgeerts, P.⁵

3
- 24144483087
- A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
- Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
- (2005) Gastroenterology , vol.129 , pp. 807-818
- Schreiber, S.¹ Rutgeerts, P.² Fedorak, R.N.³ Khaliq-Kareemi, M.⁴ Kamm, M.A.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.